ABSTRACT: 

Neuroendocrine tumors of the digestive tract (NETDT) are a subgroup of neuroendocrine tumors (NET) that develop from neuroendocrine cells located in the digestive tract wall.
This article presents the case of a 42-year-old patient diagnosed with a metastatic small bowel neuroendocrine tumor in the liver. The anatomopathological examination revealed a morphological and immunohistochemical profile consistent with a well-differentiated grade 2 digestive-origin neuroendocrine tumor with hepatic localization.
A multidisciplinary tumor board reviewed the patient’s case and recommended resection of the mass with cholecystectomy to prevent complications from planned postoperative systemic therapies (gallstone disease).
The patient underwent surgery, including mesenteric mass resection involving 10 cm of the small bowel with a sub-stenosing mass, termino-terminal small bowel anastomosis, and retrograde cholecystectomy

KEYWORDS :

neuroendocrine tumor, carcinoid syndrome, digestive tract.

REFERENCES :

1) Dasari, A., & Shen, C. (2017). “Epidemiology of gastroenteropancreatic neuroendocrine tumors.” Journal of Clinical Oncology, 35(13), 1584–1590. 

https://doi.org/10.1200/JCO.2016.70.2811
Cet article explore l’incidence, les localisations et les tendances épidémiologiques des TNETD.
2) Modlin, I. M., Lye, K. D., & Kidd, M. (2003). “A 5-decade analysis of 13,715 cases of carcinoid tumors.” Cancer, 97(4), 934–959. https://doi.org/10.1002/cncr.11152
Examine les syndromes cliniques associés aux tumeurs neuroendocrines fonctionnelles, notamment le syndrome carcinoïde.
3) WHO Classification of Tumours Editorial Board. (2019). WHO Classification of Tumours of the Digestive System. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC).
Cette source fournit des informations détaillées sur la classification des tumeurs neuroendocrines digestives selon l’OMS.
4) Kidd, M., & Modlin, I. M. (2011). “Neuroendocrine tumors of the gastrointestinal tract: An overview.” Gastroenterology Clinics of North America, 40(1), 1-16. 

https://doi.org/10.1016/j.gtc.2010.12.005

Fournit un aperçu détaillé des TNETD et de leur prise en charge.
5) Rinke, A., Müller, H. H., Schade-Brittinger, C., et al. (2009). “Placebo-controlled, double-blind, prospective phase III trial of octreotide for the treatment of metastatic carcinoid tumors.” Lancet Oncology, 10(8), 744-753.
https://doi.org/10.1016/S1470-2045(09)70169-8
Étude clinique sur l’efficacité des analogues de la somatostatine dans les tumeurs neuroendocrines.
6) Fazio, N., & Pape, U. F. (2010). “Somatostatin analogs in the management of gastroenteropancreatic neuroendocrine tumors.” Best Practice & Research Clinical Gastroenterology, 24(3), 329–340. https://doi.org/10.1016/j.bpg.2010.04.002
Cet article passe en revue les options thérapeutiques pour le traitement des TNETD, en particulier l’utilisation des analogues de la somatostatine.
7) Panzuto, F., & Fazio, N. (2016). “Targeted therapies for neuroendocrine tumors.” European Journal of Cancer, 63, 134–142. https://doi.org/10.1016/j.ejca.2016.05.013
Présentation des thérapies ciblées et des options thérapeutiques pour les tumeurs neuroendocrines.
8) Yao, J. C., Hassan, M., Phan, A., & et al. (2008). “One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.” JAMA, 301(21), 2212–2221.
https://doi.org/10.1001/jama.2009.747
Analyse des facteurs pronostiques et des stratégies de traitement des tumeurs neuroendocrines, y compris les TNETD.
9) Strosberg, J. R., & Rokke, D. (2016). “Radiolabeled somatostatin analogs in the management of neuroendocrine tumors.” Seminars in Nuclear Medicine, 46(4), 258–265. https://doi.org/10.1053/j.semnuclmed.2016.03.004
Discuter des traitements par radionucléides pour les TNETD métastatiques.